DAWN
Day One Biopharmaceuticals, Inc.
DAWN
Key terms
About DAWN
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DAWN news
Yesterday 8:13am ET Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher by TipRanks Yesterday 8:07am ET Day One Biopharmaceuticals price target raised to $33 from $30 at Needham by TipRanks Yesterday 7:50am ET Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF) by TipRanks Yesterday 6:21am ET Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN) by TipRanks Yesterday 5:42am ET Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX) by TipRanks Apr 23 6:05pm ET Buy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemda by TipRanks Apr 23 4:38pm ET Day One should rally to $17.50-$18 on approval, says JonesResearch by TipRanks Apr 23 3:58pm ET Day One confirms FDA accelerated approval of Ojemda by TipRanks Apr 23 3:24pm ET JPMorgan sees Day One moving to ‘high-teens to low-$20s’ after approval by TipRanks Apr 23 3:05pm ET Buy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospects by TipRanks Apr 23 2:31pm ET Day One up 11% to $17 after FDA grants accelerated approval by TipRanks Apr 23 2:30pm ET FDA announces accelerated approval to Day One’s tovorafenib by TipRanks Apr 22 6:10am ET Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan by TipRanks Apr 22 5:46am ET Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impact by TipRanks Apr 16 9:00am ET Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN) by TipRanks Apr 09 4:05pm ET Buy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruption by TipRanks Mar 26 7:10am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX) by TipRanks Mar 06 9:38am ET Day One Biopharmaceuticals trading resumes by TipRanks Mar 06 9:33am ET Day One Biopharmaceuticals trading halted, volatility trading pause by TipRanks Feb 29 8:31am ET Day One Biopharmaceuticals price target lowered to $33 from $35 at Wedbush by TipRanks Feb 29 8:10am ET Analysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX) by TipRanks Feb 28 7:31am ET Piper Sandler Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN) by TipRanks Feb 28 7:29am ET Day One Biopharmaceuticals price target lowered to $40 from $45 at Piper Sandler by TipRanks Feb 28 1:03am ET A New Cause for Concern: Day One Biopharmaceuticals, Inc. Adds a New Regulation Risk by TipRanks Feb 27 4:26pm ET Day One price target lowered to $35 from $45 at JonesResearch by TipRanks Feb 27 4:25pm ET Buy Rating Reaffirmed for Day One Biopharmaceuticals Amid Tovorafenib’s Promising Prospects and Financial Stability by TipRanks Feb 27 9:10am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF) by TipRanks Feb 27 7:49am ET Day One Biopharmaceuticals (DAWN) Receives a Hold from Oppenheimer by TipRanks Feb 27 6:26am ET Day One Biopharmaceuticals: A Strong Buy on Tovorafenib’s Anticipated Approval and Positive KOL Feedback by TipRanks Feb 27 5:59am ET Buy Rating Affirmed for Day One Biopharmaceuticals Amid Strong Pre-Launch Strategy and Solid Financials by TipRanks Feb 26 10:30pm ET Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN) by TipRanks
No recent press releases are available for DAWN
DAWN Financials
1-year income & revenue
Key terms
Ad Feedback
DAWN Forecasts
analyst rating
- buy
- hold
- sell
We're sorry, but this
information is
temporarily unavailable.
1-year stock price forecast
DAWN Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
